Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Sep 2025 | 178,500 | 37,500 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Sep 2025 | 144,000 | 0 | - | - | Restricted Stock Units | |
| Sionna Therapeutics Inc. | Jennifer Fitzpatrick | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 04 Sep 2025 | 10,250 | 10,250 | - | 6.1 | 62,628 | Common Stock |
| Sionna Therapeutics Inc. | Jennifer Fitzpatrick | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2025 | 10,250 | 71,435 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc. | Jennifer Fitzpatrick | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.12 per share. | 04 Sep 2025 | 10,250 | 0 | - | 23.1 | 236,980 | Common Stock |
| Cg Oncology Inc. | Hong Fang Song | Director | Sale of securities on an exchange or to another person at price $ 27.60 per share. | 03 Sep 2025 | 69,695 | 2,934,236 | - | 27.6 | 1,923,582 | Common Stock |
| Cg Oncology Inc. | Hong Fang Song | Director | Sale of securities on an exchange or to another person at price $ 28.24 per share. | 03 Sep 2025 | 30,105 | 2,904,131 | - | 28.2 | 850,165 | Common Stock |
| ANI Pharmaceuticals Inc | Antonio R. Pera | Director | Sale of securities on an exchange or to another person at price $ 94.94 per share. | 03 Sep 2025 | 7,292 | 22,660 (0%) | 0% | 94.9 | 692,302 | Common Stock |
| Cg Oncology Inc. | Leonard E. Post | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 03 Sep 2025 | 1,000 | 1,000 | - | 0.6 | 600 | Common Stock |
| Cg Oncology Inc. | Leonard E. Post | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2025 | 1,000 | 125,077 | - | - | Director Stock Option (right to buy) | |
| Cg Oncology Inc. | Leonard E. Post | Director | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 03 Sep 2025 | 1,000 | 0 | - | 28 | 28,000 | Common Stock |
| Editas Medicine Inc | Linda C. Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 2.60 per share. | 03 Sep 2025 | 710 | 69,490 (0%) | 0% | 2.6 | 1,843 | Common Stock |
| Editas Medicine Inc | Amy Parison | SVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.60 per share. | 03 Sep 2025 | 458 | 16,369 (0%) | 0% | 2.6 | 1,189 | Common Stock |
| Cg Oncology Inc. | Hong Fang Song | Director | Sale of securities on an exchange or to another person at price $ 28.99 per share. | 03 Sep 2025 | 100 | 2,903,931 | - | 29.0 | 2,899 | Common Stock |
| Cg Oncology Inc. | Hong Fang Song | Director | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 03 Sep 2025 | 100 | 2,904,031 | - | 29.0 | 2,896 | Common Stock |
| Adaptimmune Therapeutics Plc | Gavin Hilary James Wood | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.01 per share. | 02 Sep 2025 | 96,000 | 0 (0%) | 0% | 0.0 | 950 | Ordinary Shares with a nominal value of GBP0.001 per share |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 52,086 | 456,690 (0%) | 0% | 0 | Common Stock | |
| Alector Inc | Arnon Rosenthal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 02 Sep 2025 | 51,562 | 2,350,220 (2%) | 0% | 2.5 | 128,740 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 41,669 | 250,013 | - | - | Restricted Stock Units | |
| Alector Inc | Saraswati Kenkare-Mitra | President and Head of R&D | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 02 Sep 2025 | 23,638 | 543,339 (0%) | 0% | 2.5 | 59,019 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.19 per share. | 02 Sep 2025 | 22,127 | 434,563 (0%) | 0% | 2.2 | 48,458 | Common Stock |
| Vir Biotechnology Inc | Vicki L. Sato | Director | Sale of securities on an exchange or to another person at price $ 4.99 per share. | 02 Sep 2025 | 22,000 | 1,254,391 (1%) | 0% | 5.0 | 109,811 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 156,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 136,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 176,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Spyre Therapeutics Inc. | Scott L. Burrows | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.26 per share. | 02 Sep 2025 | 18,428 | 97,994 (0%) | 0% | 16.3 | 299,639 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Joseph Shulman | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 105.30 per share. | 02 Sep 2025 | 16,781 | 8,509 (0%) | 0% | 105.3 | 1,767,006 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 73.70 per share. | 02 Sep 2025 | 16,288 | 737,131 (0%) | 0% | 73.7 | 1,200,393 | Common Stock |
| Alector Inc | Neil Berkley | Principal Financial Officer | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 02 Sep 2025 | 15,842 | 346,570 (0%) | 0% | 2.5 | 39,554 | Common Stock |
| Arrowhead Pharmaceuticals Inc | James Hamilton | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 02 Sep 2025 | 15,000 | 247,122 (0%) | 0% | 25 | 375,000 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Joseph Shulman | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 14,687 | 22,813 | - | - | Stock Options (Right to Buy) | |
| Rhythm Pharmaceuticals Inc. | Joseph Shulman | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.66 per share. | 02 Sep 2025 | 14,687 | 25,290 (0%) | 0% | 30.7 | 450,303 | Common Stock |
| Axsome Therapeutics Inc | Roger A. Jeffs | Director | Sale of securities on an exchange or to another person at price $ 123.68 per share. | 02 Sep 2025 | 13,464 | 57,510 (0%) | 0% | 123.7 | 1,665,228 | Common Stock |
| Iovance Biotherapeutics Inc | Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 12,697 | 111,857 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 12,306 | 105,939 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.63 per share. | 02 Sep 2025 | 10,500 | 733,719 (0%) | 0% | 74.6 | 783,636 | Common Stock |
| Iovance Biotherapeutics Inc | Frederick G. Vogt | Director, Interim CEO & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 10,417 | 20,385 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 73.54 per share. | 02 Sep 2025 | 9,900 | 743,819 (0%) | 0% | 73.5 | 728,006 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.22 per share. | 02 Sep 2025 | 9,500 | 744,219 (0%) | 0% | 74.2 | 705,090 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 8,790 | 52,738 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 8,790 | 52,738 | - | - | Restricted Stock Units | |
| Entrada Therapeutics Inc | Dipal Doshi | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.43 per share. | 02 Sep 2025 | 8,723 | 415,664 | - | 5.4 | 47,368 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.33 per share. | 02 Sep 2025 | 7,800 | 736,019 (0%) | 0% | 74.3 | 579,751 | Common Stock |
| Iovance Biotherapeutics Inc | Finckenstein Friedrich Graf | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.19 per share. | 02 Sep 2025 | 6,448 | 105,409 (0%) | 0% | 2.2 | 14,121 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.19 per share. | 02 Sep 2025 | 6,250 | 99,689 (0%) | 0% | 2.2 | 13,688 | Common Stock |
| Alector Inc | Grace Wong-Sarad | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 02 Sep 2025 | 5,910 | 103,448 (0%) | 0% | 2.5 | 14,756 | Common Stock |
| Stoke Therapeutics Inc | Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 19.87 per share. | 02 Sep 2025 | 5,501 | 18,469 (0%) | 0% | 19.9 | 109,325 | Common Stock |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 5,470 | 32,817 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 5,470 | 215,324 (0%) | 0% | 0 | Common Stock | |
| Vaxcyte Inc | Grant E. Pickering | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 4,563 | 511,684 | - | 31.6 | 144,008 | Common Stock |
| Iovance Biotherapeutics Inc | Finckenstein Friedrich Graf | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 3,907 | 7,813 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 3,516 | 7,033 | - | - | Restricted Stock Units | |
| Vaxcyte Inc | Grant E. Pickering | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 3,420 | 508,264 | - | 31.6 | 107,935 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.15 per share. | 02 Sep 2025 | 3,412 | 733,719 (0%) | 0% | 74.1 | 252,990 | Common Stock |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Sale of securities on an exchange or to another person at price $ 73.62 per share. | 02 Sep 2025 | 2,977 | 47,875 (0%) | 0% | 73.6 | 219,161 | Common Stock |
| Vaxcyte Inc | Grant E. Pickering | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 2,857 | 516,247 | - | 31.6 | 90,167 | Common Stock |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.19 per share. | 02 Sep 2025 | 2,467 | 212,857 (0%) | 0% | 2.2 | 5,403 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 2,381 | 128,628 | - | 31.6 | 75,144 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 75.22 per share. | 02 Sep 2025 | 2,300 | 733,719 (0%) | 0% | 75.2 | 173,015 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Joseph Shulman | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.35 per share. | 02 Sep 2025 | 2,094 | 10,603 (0%) | 0% | 27.4 | 57,271 | Common Stock |
| Rhythm Pharmaceuticals Inc. | Joseph Shulman | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 2,094 | 16,750 | - | - | Stock Options (Right to Buy) | |
| Entrada Therapeutics Inc | Natarajan Sethuraman | President, Research & Develop. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.43 per share. | 02 Sep 2025 | 1,760 | 197,899 | - | 5.4 | 9,557 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.43 per share. | 02 Sep 2025 | 1,746 | 179,059 | - | 5.4 | 9,481 | Common Stock |
| Entrada Therapeutics Inc | Kory J. Wentworth | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.43 per share. | 02 Sep 2025 | 1,734 | 118,936 | - | 5.4 | 9,416 | Common Stock |
| Vaxcyte Inc | Jim Wassil | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 1,587 | 147,699 | - | 31.6 | 50,086 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 1,429 | 127,199 | - | 31.6 | 45,099 | Common Stock |
| Vaxcyte Inc | Jim Wassil | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 1,429 | 146,270 | - | 31.6 | 45,099 | Common Stock |
| MiNK Therapeutics Inc | Brian J. Corvese | Director | Grant, award, or other acquisition of securities at price $ 13.86 per share. | 02 Sep 2025 | 1,290 | 48,441 | - | 13.9 | 17,879 | Common Stock |
| MiNK Therapeutics Inc | Barbara Ryan | Director | Grant, award, or other acquisition of securities at price $ 13.86 per share. | 02 Sep 2025 | 1,281 | 20,805 | - | 13.9 | 17,755 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 1,270 | 131,009 | - | 31.6 | 40,081 | Common Stock |
| Vaxcyte Inc | Jim Wassil | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 1,270 | 149,286 | - | 31.6 | 40,081 | Common Stock |
| MiNK Therapeutics Inc | Peter Behner | Director | Grant, award, or other acquisition of securities at price $ 13.86 per share. | 02 Sep 2025 | 1,173 | 18,649 | - | 13.9 | 16,258 | Common Stock |
| MiNK Therapeutics Inc | Ulf Wiinberg | Director | Grant, award, or other acquisition of securities at price $ 13.86 per share. | 02 Sep 2025 | 1,011 | 18,971 | - | 13.9 | 14,012 | Common Stock |
| MiNK Therapeutics Inc | Robert Peter Kadlec | Director | Grant, award, or other acquisition of securities at price $ 13.86 per share. | 02 Sep 2025 | 975 | 17,908 | - | 13.9 | 13,514 | Common Stock |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Sale of securities on an exchange or to another person at price $ 74.11 per share. | 02 Sep 2025 | 923 | 46,952 (0%) | 0% | 74.1 | 68,404 | Common Stock |
| Vaxcyte Inc | Harpreet S. Dhaliwal | Chief Technical Ops Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 783 | 35,338 | - | 31.6 | 24,711 | Common Stock |
| Vaxcyte Inc | Harpreet S. Dhaliwal | Chief Technical Ops Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 464 | 34,874 | - | 31.6 | 14,644 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 325 | 26,638 | - | 31.6 | 10,257 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 72.49 per share. | 02 Sep 2025 | 300 | 753,419 (0%) | 0% | 72.5 | 21,746 | Common Stock |
| Vaxcyte Inc | Harpreet S. Dhaliwal | Chief Technical Ops Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 291 | 36,121 | - | 31.6 | 9,184 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 02 Sep 2025 | 242 | 26,963 | - | 31.6 | 7,638 | Common Stock |
| Avidity Biosciences Inc | Kathleen P. Gallagher | Chief Program Officer | Sale of securities on an exchange or to another person at price $ 47.42 per share. | 02 Sep 2025 | 188 | 50,204 | - | 47.4 | 8,915 | Common Stock |
| Halozyme Therapeutics Inc | Bernadette M. Connaughton | Director | Sale of securities on an exchange or to another person at price $ 71.71 per share. | 02 Sep 2025 | 100 | 50,852 (0%) | 0% | 71.7 | 7,171 | Common Stock |
| Lixte Biotechnology Holdin... | Peter Stazzone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 50,000 | 50,000 | - | - | Options to Purchase Common Stock | |
| BioAtla Inc | Jay M. Short | Director, Chief Executive Officer, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.46 per share. | 31 Aug 2025 | 6,347 | 2,243,678 | - | 0.5 | 2,891 | Common Stock |
| BioAtla Inc | Eric Sievers | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.46 per share. | 31 Aug 2025 | 2,729 | 364,574 | - | 0.5 | 1,243 | Common Stock |
| BioAtla Inc | Richard A. Waldron | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.46 per share. | 31 Aug 2025 | 2,371 | 338,521 | - | 0.5 | 1,080 | Common Stock |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2025 | 1,693 | 3,387 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2025 | 1,693 | 16,930 (0%) | 0% | - | Common Stock | |
| BioAtla Inc | Christian Vasquez | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.46 per share. | 31 Aug 2025 | 1,566 | 283,564 | - | 0.5 | 713 | Common Stock |
| Equillium Inc | Bruce D. Steel | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 1,695,000 | 1,695,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Stephen Connelly | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 1,025,000 | 1,025,000 | - | - | Employee Stock Option (right to buy) | |
| Equillium Inc | Christine Zedelmayer | Sr. Vice President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 725,000 | 725,000 | - | - | Employee Stock Option (right to buy) | |
| Zai Lab Limited - ADR | Samantha Du | Director, Chairperson & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.20 per share. | 29 Aug 2025 | 604,376 | 1,141,338 (2%) | 1% | 1.2 | 725,251 | American Depositary Shares |
| Zai Lab Limited - ADR | Samantha Du | Director, Chairperson & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 604,376 | 0 | - | - | Stock Options (Right to Buy) | |
| Equillium Inc | Penny Tom | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 525,000 | 525,000 | - | - | Employee Stock Option (right to buy) | |
| Lexeo Therapeutics Inc. | Louis Tamayo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 280,000 | 280,000 | - | - | Stock Option (right to buy) | |
| Zai Lab Limited - ADR | Samantha Du | Director, Chairperson & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.59 per share. | 29 Aug 2025 | 251,319 | 890,019 (1%) | 0% | 32.6 | 8,190,486 | American Depositary Shares |
| CorMedix Inc | Elizabeth Hurlburt | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 69,686 | 185,414 (0%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Susan Blum | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 69,686 | 69,686 (0%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Beth Zelnick Kaufman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 69,686 | 189,298 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 20.13 per share. | 29 Aug 2025 | 45,996 | 91,585 (0%) | 0% | 20.1 | 925,858 | Common Stock |
| Lexeo Therapeutics Inc. | Louis Tamayo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 45,000 | 45,000 | - | 0 | Common Stock | |
| Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 20.14 per share. | 29 Aug 2025 | 14,922 | 18,176 (0%) | 0% | 20.1 | 300,492 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 20.14 per share. | 29 Aug 2025 | 14,860 | 137,581 (0%) | 0% | 20.1 | 299,260 | Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 9,743 | 9,743 | - | - | Stock Option (right to buy) | |
| Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.07 per share. | 29 Aug 2025 | 9,150 | 33,098 (0%) | 0% | 7.1 | 64,691 | Common Stock |
| Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 9,150 | 15,801 | - | - | Stock Option (Right to Buy) | |
| Sionna Therapeutics Inc. | Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 25.08 per share. | 29 Aug 2025 | 8,836 | 38,532 | - | 25.1 | 221,607 | Common Stock |
| Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 20.07 per share. | 29 Aug 2025 | 6,345 | 11,831 (0%) | 0% | 20.1 | 127,317 | Common Stock |
| Nuvalent Inc - Ordinary Sh... | Henry E. Pelish | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 3,000 | 5,085 | - | - | Stock Option (Right to Buy) | |
| Nuvalent Inc - Ordinary Sh... | Henry E. Pelish | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 29 Aug 2025 | 3,000 | 65,963 | - | 1.1 | 3,240 | Class A Common Stock |
| Vaxcyte Inc | Elvia Cowan | SVP, FINANCE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2025 | 2,810 | 27,205 | - | 0 | Common Stock | |
| Nuvalent Inc - Ordinary Sh... | Henry E. Pelish | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 2,007 | 0 | - | - | Stock Option (Right to Buy) | |
| Nuvalent Inc - Ordinary Sh... | Henry E. Pelish | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.87 per share. | 29 Aug 2025 | 2,007 | 62,963 | - | 0.9 | 1,746 | Class A Common Stock |
| Biogen | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 1,669 | 0 | - | - | Restricted Stock Unit | |
| Biogen | Priya Singhal | Head of Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 1,669 | 7,096 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc | Steven Frank | Director | Grant, award, or other acquisition of securities at price $ 8.31 per share. | 29 Aug 2025 | 1,353 | 16,052 (0%) | 0% | 8.3 | 11,243 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 29 Aug 2025 | 1,029 | 152,441 (0%) | 0% | 20 | 20,580 | Common Stock |
| Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 29 Aug 2025 | 850 | 23,948 (0%) | 0% | 20 | 17,000 | Common Stock |
| Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.07 per share. | 29 Aug 2025 | 850 | 24,798 (0%) | 0% | 7.1 | 6,010 | Common Stock |
| Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 850 | 24,951 | - | - | Stock Option (Right to Buy) | |
| Biogen | Priya Singhal | Head of Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 132.22 per share. | 29 Aug 2025 | 807 | 6,289 (0%) | 0% | 132.2 | 106,702 | Common Stock |
| Sionna Therapeutics Inc. | Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 25.18 per share. | 29 Aug 2025 | 748 | 47,368 | - | 25.2 | 18,835 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 8.31 per share. | 29 Aug 2025 | 676 | 90,436 (0%) | 0% | 8.3 | 5,618 | Common Stock |
| Biocryst Pharmaceuticals Inc | Amy E. McKee | Director | Grant, award, or other acquisition of securities at price $ 8.31 per share. | 29 Aug 2025 | 676 | 41,007 (0%) | 0% | 8.3 | 5,618 | Common Stock |
| Moderna | Stephen Hoge | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 651 | 1,453,827 (0%) | 0% | - | Common Stock | |
| Moderna | Stephen Hoge | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 651 | 1,304 | - | - | Restricted Stock Units | |
| Biogen | Priya Singhal | Head of Development | Sale of securities on an exchange or to another person at price $ 133.55 per share. | 29 Aug 2025 | 517 | 5,772 (0%) | 0% | 133.5 | 69,045 | Common Stock |
| Moderna | Stephen Hoge | President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.47 per share. | 29 Aug 2025 | 315 | 1,453,512 (0%) | 0% | 24.5 | 7,708 | Common Stock |
| Moderna | Shannon Thyme Klinger | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 232 | 466 | - | - | Restricted Stock Units | |
| Moderna | Shannon Thyme Klinger | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2025 | 232 | 28,283 (0%) | 0% | - | Common Stock | |
| Moderna | Shannon Thyme Klinger | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.47 per share. | 29 Aug 2025 | 113 | 28,170 (0%) | 0% | 24.5 | 2,765 | Common Stock |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.25 per share. | 28 Aug 2025 | 546,938 | 617,919 | - | 70.3 | 38,422,395 | Common Stock |
| Adaptimmune Therapeutics Plc | William C. Bertrand | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.01 per share. | 28 Aug 2025 | 207,000 | 986,352 (0%) | 0% | 0.0 | 2,091 | Ordinary Shares with a nominal value of GBP0.001 per share |
| Shattuck Labs Inc | Mona Ashiya | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2025 | 66,300 | 66,300 | - | - | Stock Option (Right to Buy) | |
| Shattuck Labs Inc | Daniel G. Baker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2025 | 66,300 | 66,300 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.66 per share. | 28 Aug 2025 | 47,040 | 261,420 (0%) | 0% | 6.7 | 313,286 | Common Stock |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2025 | 47,040 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Sale of securities on an exchange or to another person at price $ 7.92 per share. | 28 Aug 2025 | 42,232 | 219,188 (0%) | 0% | 7.9 | 334,515 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 49.39 per share. | 28 Aug 2025 | 25,000 | 305,871 | - | 49.4 | 1,234,700 | Common Stock |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2025 | 25,000 | 1,072,015 | - | - | Stock Option (Right to Buy) | |
| Avidity Biosciences Inc | Sarah Boyce | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.24 per share. | 28 Aug 2025 | 25,000 | 330,871 | - | 1.2 | 31,000 | Common Stock |
| Gilead Sciences | Daniel P. O'Day | Director, Chairman & CEO | Sale of securities on an exchange or to another person at price $ 113.63 per share. | 28 Aug 2025 | 10,000 | 595,725 (0%) | 0% | 113.6 | 1,136,300 | Common Stock |
| CalciMedica Inc | Eric W. Roberts | Director, CHIEF BUSINESS OFFICER, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.86 per share. | 28 Aug 2025 | 9,200 | 70,107 | - | 2.9 | 26,340 | Common Stock |
| Spero Therapeutics Inc | Ankit Mahadevia | Director | Sale of securities on an exchange or to another person at price $ 1.97 per share. | 28 Aug 2025 | 6,572 | 703,294 (3%) | 0% | 2.0 | 12,947 | Common Stock |
| Spero Therapeutics Inc | Timothy Keutzer | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.97 per share. | 28 Aug 2025 | 1,695 | 739,744 (3%) | 0% | 2.0 | 3,339 | Common Stock |
| CalciMedica Inc | Eric W. Roberts | Director, CHIEF BUSINESS OFFICER, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.74 per share. | 28 Aug 2025 | 800 | 70,907 | - | 2.7 | 2,192 | Common Stock |
| DarioHealth Corp | Steven Nelson | President and CCO | Purchase of securities on an exchange or from another person at price $ 0.53 per share. | 27 Aug 2025 | 40,000 | 95,000 (4%) | 1% | 0.5 | 21,200 | Common Stock |
| Axsome Therapeutics Inc | Roger A. Jeffs | Director | Sale of securities on an exchange or to another person at price $ 121.60 per share. | 27 Aug 2025 | 20,000 | 90,974 (0%) | 0% | 121.6 | 2,432,000 | Common Stock |
| Axsome Therapeutics Inc | Roger A. Jeffs | Director | Sale of securities on an exchange or to another person at price $ 122.30 per share. | 27 Aug 2025 | 20,000 | 110,974 (0%) | 0% | 122.3 | 2,446,000 | Common Stock |
| Axsome Therapeutics Inc | Roger A. Jeffs | Director | Sale of securities on an exchange or to another person at price $ 121.27 per share. | 27 Aug 2025 | 20,000 | 70,974 (0%) | 0% | 121.3 | 2,425,400 | Common Stock |
| Rocket Pharmaceuticals Inc | Elisabeth Bjork | Director | Purchase of securities on an exchange or from another person at price $ 3.41 per share. | 27 Aug 2025 | 10,000 | 40,000 (0%) | 0% | 3.4 | 34,100 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 59.25 per share. | 27 Aug 2025 | 4,000 | 9,130 (0%) | 0% | 59.3 | 237,000 | Common Stock |
| Cadrenal Therapeutics Inc | Quang X. Pham | Director, CEO and Chairman, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 13.99 per share. | 27 Aug 2025 | 3,836 | 214,497 | - | 14.0 | 53,666 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.63 per share. | 27 Aug 2025 | 3,250 | 23,000 | - | 20.6 | 67,039 | Common Stock |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 3,250 | 108,306 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Aug 2025 | 3,250 | 26,250 | - | 2.5 | 8,060 | Common Stock |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 27 Aug 2025 | 1,600 | 31,733 | - | 14.0 | 22,392 | Common Stock |
| Moderna | Stephen Hoge | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 1,437 | 14,368 | - | - | Restricted Stock Units | |
| Moderna | Stephen Hoge | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 1,437 | 1,453,556 (0%) | 0% | - | Common Stock | |
| Cadrenal Therapeutics Inc | Quang X. Pham | Director, CEO and Chairman, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 13.99 per share. | 27 Aug 2025 | 1,193 | 213,304 | - | 14.0 | 16,690 | Common Stock |
| Moderna | James M Mock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 774 | 17,715 (0%) | 0% | - | Common Stock | |
| Moderna | James M Mock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 774 | 7,736 | - | - | Restricted Stock Units | |
| Moderna | Shannon Thyme Klinger | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 774 | 28,257 (0%) | 0% | - | Common Stock | |
| Moderna | Shannon Thyme Klinger | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 774 | 7,736 | - | - | Restricted Stock Units | |
| Moderna | Stephen Hoge | President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.73 per share. | 27 Aug 2025 | 695 | 1,452,861 (0%) | 0% | 24.7 | 17,187 | Common Stock |
| Moderna | Stephen Hoge | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 611 | 1,453,472 (0%) | 0% | - | Common Stock | |
| Moderna | Stephen Hoge | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 611 | 3,663 | - | - | Restricted Stock Units | |
| Cadrenal Therapeutics Inc | Matthew K. Szot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 27 Aug 2025 | 400 | 31,333 | - | 14 | 5,600 | Common Stock |
| Moderna | James M Mock | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.73 per share. | 27 Aug 2025 | 375 | 17,340 (0%) | 0% | 24.7 | 9,274 | Common Stock |
| Moderna | Shannon Thyme Klinger | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.73 per share. | 27 Aug 2025 | 375 | 27,882 (0%) | 0% | 24.7 | 9,274 | Common Stock |
| Moderna | James M Mock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 329 | 1,973 | - | - | Restricted Stock Units | |
| Moderna | James M Mock | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 329 | 17,669 (0%) | 0% | - | Common Stock | |
| Moderna | Shannon Thyme Klinger | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 329 | 28,211 (0%) | 0% | - | Common Stock | |
| Moderna | Shannon Thyme Klinger | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 329 | 1,973 | - | - | Restricted Stock Units | |
| Moderna | Stephen Hoge | President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.10 per share. | 27 Aug 2025 | 296 | 1,453,176 (0%) | 0% | 25.1 | 7,430 | Common Stock |
| Moderna | James M Mock | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.10 per share. | 27 Aug 2025 | 160 | 17,509 (0%) | 0% | 25.1 | 4,016 | Common Stock |
| Moderna | Shannon Thyme Klinger | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.10 per share. | 27 Aug 2025 | 160 | 28,051 (0%) | 0% | 25.1 | 4,016 | Common Stock |
| SAB Biotherapeutics Inc | Samuel J. Reich | Director, CEO & EXECUTIVE CHAIRMAN | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 4,800,000 | 4,800,000 | - | - | Stock Option (right to buy) | |
| SAB Biotherapeutics Inc | Eddie J. Sullivan | Director, PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 3,000,000 | 3,000,000 | - | - | Stock Option (right to buy) | |
| SAB Biotherapeutics Inc | Alexandra Kropotova | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 2,400,000 | 2,400,000 | - | - | Stock Option (right to buy) | |
| SAB Biotherapeutics Inc | Lucy To | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 1,200,000 | 1,200,000 | - | - | Stock Option (right to buy) | |
| SAB Biotherapeutics Inc | Christoph Lawrence Bausch | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 600,000 | 600,000 | - | - | Stock Option (right to buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2025 | 100,000 | 1,247,365 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.60 per share. | 26 Aug 2025 | 100,000 | 23,400 | - | 14.6 | 1,459,760 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 26 Aug 2025 | 100,000 | 123,400 | - | 0.2 | 18,000 | Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 26 Aug 2025 | 100,000 | 5,373,034 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.84 per share. | 26 Aug 2025 | 100,000 | 954,229 | - | 4.8 | 484,000 | Class A Common Stock |
| Recursion Pharmaceuticals ... | Christopher Gibson | Director, Chief Executive Officer | 26 Aug 2025 | 100,000 | 1,054,229 | - | 0 | Class A Common Stock | ||
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 20,000 | 20,000 | - | - | Stock Option (right ot buy) | |
| Sionna Therapeutics Inc. | Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 24.96 per share. | 26 Aug 2025 | 17,574 | 547,343 | - | 25.0 | 438,647 | Common Stock |
| Sionna Therapeutics Inc. | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 26 Aug 2025 | 17,574 | 564,917 | - | 6.1 | 107,377 | Common Stock |
| Sionna Therapeutics Inc. | Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2025 | 17,574 | 210,568 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc. | Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 25.97 per share. | 26 Aug 2025 | 16,098 | 48,116 | - | 26.0 | 418,065 | Common Stock |
| Alector Inc | Paula Hammond | Director | Sale of securities on an exchange or to another person at price $ 2.36 per share. | 26 Aug 2025 | 14,000 | 74,909 (0%) | 0% | 2.4 | 32,998 | Common Stock |
| UroGen Pharma Ltd | Cynthia M. Butitta | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 10,000 | 10,000 | - | - | Stock Option (right ot buy) |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.